Nevertheless, enhanced levels of CD276 were more evident in older patients, those with high-grade urothelial carcinoma, and individuals exhibiting lymph node or distant metastases during advanced stages of the disease (Figure 2, p<0.05). This evidence concerns the gene CD276 and urothelial carcinoma.